Diagnosis in the early stages of hereditary transthyretin (ATTR) amyloidosis is imperative to support timely treatment to prevent or delay disease progression. Genetic testing in the setting of genetic counselling enables identification of carriers of a TTR gene mutation who are therefore at risk of developing TTR-associated disease. Knowledge of different genotypes and how they manifest in symptomatic disease should facilitate development of a structured and targeted approach to enable diagnosis of symptomatic disease in ATTR amyloidosis mutation carriers on the first manifestation of the earliest detectable sign or symptom. A group of experts from across Europe, Israel and Japan met to reach a consensus on such an approach. The proposed approach involves establishing a baseline for key clinical parameters, determination of the timing and frequency of follow-up in TTR mutation carriers based on a predicted age of disease onset, and recognition of the likely initial clinical signs and symptoms aligned with the phenotype of the specific TTR gene mutation and family history. Minimum criteria for diagnosis of symptomatic disease have been agreed, which it is hoped will ensure diagnosis of ATTR amyloidosis at the earliest possible stage in people with a known TTR mutation.
Background: Transthyretin amyloidosis (ATTR) is a multisystem, progressive, and potentially fatal condition. It is significantly under-recognized, leading to delayed diagnosis and treatment and poor outcomes. The CARABELA-ATTR initiative aims to address the challenges of ATTR management in the Spanish healthcare system. Methods: This initiative promotes collaboration between scientific societies, clinicians, and the pharmaceutical industry to optimize ATTR care using lean methodology. It included four phases: (1) characterization of ATTR clinical pathways; (2) validation and prioritization of areas for improvement and selection of quality indicators (QIs); (3) co-creation of solutions; and (4) dissemination of results. Results: A generic ATTR patient journey was defined, identifying four healthcare models with varying coordination and resources. Multidisciplinary discussions identified 13 areas for improvement, including deficient multidisciplinary coordination, lack of standardized diagnostic protocols, and uneven resource distribution. A set of QIs covering all aspects of care was defined. Validated solutions included establishing multidisciplinary teams, standardizing diagnostic and treatment protocols, and ensuring equitable access to advanced diagnostics and treatments. Conclusions: The CARABELA-ATTR initiative provides a framework that emphasizes multidisciplinary coordination, diagnostic and treatment protocols, continuous education for healthcare professionals and patients, and equitable access to resources, aiming to improve patient outcomes and quality of life.